All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MDS Alliance.

  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MDS Hub
Brought to you by Scientific Education Support
View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EBMT 2023

Share:

Apr 24, 2023

X post image

31 May 2023

📖 #EBMT23 | Did you miss the @MDS_Hub coverage of the 49th Annual Meeting of @TheEBMT?

You can catch up via the link below 👇
https://t.co/c63bCPaoeR

#MDS #leukemia

View on 

X post image

27 Apr 2023

📢 #EBMT23 | We hope you enjoyed following our congress coverage and live updates.

Watch out for post-congress insights and key points on our Twitter page.

#MDSsm #MDS

View on 

X post image

26 Apr 2023

Congress | #EBMT23 @CarmeloGurnari @unitorvergata @ClevelandClinic discusses IPSS-M and transplant interactions in patients with #MDS. The incorporation of molecular data may improve the prognostication of patients with MDS undergoing HSCT. #MDSsm #medicalcongress

View on 

X post image

26 Apr 2023

Congress | #EBMT23 Raynier Devillier, @paoli_calmettes presents a phase II trial on the impact of higher doses of busulfan in FB regimens on outcomes for pts unfit for MAC who received allo-HSCT for AML/MDS. 3 or 4 days of busulfan did not improve outcomes over 2 days. #MDS

View on 

X post image

25 Apr 2023

CONGRESS|#EBMT23 Charlotte Niemeyer, Freiburg University Medical Center gives an overview of #MDS presenting in paediatric patients and discusses potential strategies of stem cell transplantation to improve curative outcomes #mdssm #medicalcongress

View on 

X post image

25 Apr 2023

CONGRESS|#EBMT23 Ana Pérez-González @CBGP_Madrid gives a presentation on allo-HSCT in patients with IDH mutated #MDS and the associated outcomes and prognostic factors.T he prognosis of IDH1 and IDH2 mutations is comparable, with a 2-year OS exceeding 70% #mdssm #medicalcongress

View on 

X post image

24 Apr 2023

CONGRESS|#EBMT23 Ambroise Marçais evaluates the feasibility and benefit of 5-aza maintenance therapy after allo-HSCT for patients with #MDS. Treatment was found to be feasible and well tolerated and can improves outcome by limiting relapse incidence #mdssm #medicalcongress

View on 

X post image

24 Apr 2023

CONGRESS|#EBMT23 Brigitte Strahm presents analysis on the impact of mutated UBTF-TD on outcomes of HSCT for paediatric #MDS with excess blast. Patients with normal karyotype and UBTFmut had a significantly inferior DFS compared to UBTFwt #mdssm #medicalcongress

View on 

X post image

24 Apr 2023

CONGRESS|#EBMT23 Minyoung Youn presents analysis of lymphocyte and cytokine changes that may correlate with GVHD in patients with #MDS and treated with briquilimab/Flu/TBI for HCT. No severe cGVHD was observed and CD34+ and CD3+ doses were similar #mdssm #medicalcongress

View on 

X post image

24 Apr 2023

CONGRESS|#EBMT23 Bruna Puglisi presents analysis of azacitidine as maintenance after allo-HSCT in patients with high risk AML and #MDS. Relapse incidence at 2 years was 21% in patients on treatment versus 38% on control and was well tolerated #mdssm #medicalcongress

View on 

X post image

24 Apr 2023

CONGRESS|#EBMT23 Marie Robin discusses treatment algorithms in #MDS. She presents data on overall survival associated with the IPSS model as well as HSCT versus non-HSCT treatment and overall optimisation for patients #mdssm #medicalcongress

View on 

X post image

22 Apr 2023

📢 CONGRESS | The #MDS Hub will be virtually attending #EBMT 2023.

📅 April 23–26, 2023

📍 Paris and online

Keep an eye on our Twitter page @MDS_Hub for live coverage throughout the congress!

#EBMT23 #MDSsm #MDS

View on 

X post image

23 Mar 2023

#EBMT23 | CONGRESS
Only a month away until @MDS_Hub virtually attends the 49th Annual Meeting of the @TheEBMT

📍 Location: Paris, France and online
📅 When: April 23–26

#MDSsm #MDS

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EBMT 2023

Newsletter

Subscribe to get the best content delivered to your inbox